insights_auto
Why is ALNY up 3.58%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$232.56
arrow_upward
+3.58%(+8.04) 1D
Oct 9, 10:25:29 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$224.74
High
$232.79
Low
$222.70
Mkt. cap
31.08B
Avg. vol.
1.50M
Volume
120.32K
P/E ratio
39.53
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$224.74
High
$232.79
Low
$222.70
Mkt. cap
31.08B
Avg. vol.
1.50M
Volume
120.32K
P/E ratio
39.53
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Zacks
·
1 hour ago
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Zacks
·
23 hours ago
Here's Why You Should Add LPCN Stock to Your Portfolio Now
GuruFocus
·
23 hours ago
ALNY Maintained by RBC Capital -- Price Target Lowered to $345
Zacks
·
23 hours ago
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.